Patent Foundation Inks Licensing Pact With Carter-Wallace
28, 2001-- The
University of Virginia Patent Foundation of Charlottesville, Va.,
has entered into a licensing agreement with Carter-Wallace, Inc.
of New York for a new treatment of nervous system disorders using
a derivative of felbamate, a drug approved in 1993 for treating
patients with epilepsy.
Carter-Wallace holds worldwide rights
for development and marketing of the licensed product. Financial
terms of the agreement were not disclosed.
For years, scientists have sought
to find new or improved treatments for patients with central nervous
system disorders, such as epilepsy, stroke, migraines, and neurological
In recent years, the laboratory directed
by Timothy Macdonald, U.Va. professor and chairman of the Department
of Chemistry, has studied felbamate in an attempt to create new,
more effective drugs with fewer side effects. Preliminary animal
studies have shown that some of these new chemical derivatives may
be safer and more effective than felbamate.
Macdonalds research focuses
on the application of organic chemical theory to biological problems.
His current research seeks to understand the molecular interactions
and mechanisms of small molecule-protein interactions, which has
enabled him to develop new drugs with less potential for toxic side
About Carter-Wallace, Inc.
Carter-Wallace, Inc. was founded
in 1880 as the Carter Medicine Company and, at that time, marketed
only a single product, Carters Little Liver Pills. Since then,
the company has grown through mergers, acquisitions, and alliances
to become an international marketer of pharmaceuticals, diagnostics,
and consumer and health-care products.
About the University of
Virginia Patent Foundation
The University of Virginia Patent
Foundation is a not-for-profit corporation affiliated with University
of Virginia, and is responsible for licensing to business and industry
the intellectual property discovered and created in University laboratories
Contact: Charlotte Crystal, (804)